Saarland University
Blood-Based MicroRNA Signatures Can Distinguish Individuals With Lung Cancer
A retrospective cohort study uncovered microRNA signatures that could tell lung cancer patients apart from others, including patients with other, non-tumor lung conditions.
At the ICG-13 conference, BGI previewed a high-throughput sequencer, MGISEQ-T7, that will be commercially available in 2019 and have a throughput of up to 20,000 genomes per year.
Researchers have demonstrated that they can detect more miRNAs, as well as other small RNA molecules, by sequencing these samples rather than using microarrays.
BGI, Hummingbird Diagnostics to Develop miRNA Tests for Neurodegenerative Disorders
The partners will use Hummingbird's miRNA database and expertise in sample preparation as well as BGI's BGISEQ sequencer and analysis pipeline to develop targeted miRNA IVD assays.
Hummingbird Diagnostics, Saarland University Form Biomarker Validation Partnership
The partners plan to validate blood-based microRNAs as biomarkers for the early detection of pulmonary and neurodegenerative diseases.